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Summary During 1968-1980, 1176 women aged 16-50 years with newly diagnosed breast cancer and a like
number of matched controls were interviewed at 9 teaching hospitals in London and Oxford and asked about
their use of oral contraceptives. The results were reassuring. A few statistically significant differences in oral
contraceptive use were found between the breast cancer and control groups, but the data were subdivided in
many ways so that some "significant" differences would have been expected through the play of chance alone.
Certainly no patterns of risk emerged which would suggest that any of the associations were causal. It must
be stressed, however, that the data are still sparse in some importanr subcategories-for example, only small
numbers of both cases and controls had prolonged oral contraceptive use before their first term pregnancy.
For this reason, it is important that information on the possible relationship between pill use and breast
cancer should continue to be collected. Women who had never used oral contraceptives presented with
appreciably more advanced tumours than those who had been using oral contraceptives during the year
before detection of cancer, while past users were in an intermediate position. These differences in staging were
reflected in the pattern of survival. Possible explanations for these observations include "surveillance bias"
among oral contraceptive users leading to earlier diagnosis and a beneficial biological effect of oral
contraceptives on tumour growth and spread. Women with breast cancer reported never having used any
method of contraception and heavy cigarette smoking (> 15 per day) significantly less often than controls. We
could find no obvious explanation for the former observation, but suspect that the latter reflects the
unrepresentative smoking habits of our hospital controls rather than a protective effect of smoking against
breast cancer.
In December 1968, we began a case-control study of
the use of oral contraceptives by women admitted
to hospital for primary treatment of cancer of the
breast. Since then, 3 progress reports have been
published concerning 90, 322, and 621 cases
respectively while, in addition, a detailed analysis of
oral contraceptive use before first term pregnancy
by 1176 cases has been described (Vessey et al.,
1972, 1975, 1979, 1982). None of the results has
provided much indication of any relationship, either
positive or negative, between pill use and breast
cancer risk. We now present a brief summary of our
findings (other than those already given by Vessey
et al., 1982) from the final total of 1176 patients
with cancer of the breast admitted to hospital
before the end of the study, on September 30th,
1980.
Subjects and methods
In brief, married women aged 16-50y, who were
under treatment for newly diagnosed and
histologically proven breast cancer at University
College, the Royal Free, the Middlesex, Charing
Cross, Guy's & Mount Vernon hospitals, London
and the Radcliffe Infirmary, John Radcliffe and
Churchill hospitals, Oxford, were interviewed by a
trained medical social worker or nurse about their
medical, social, obstetric, menstrual, and
contraceptive histories. For each patient a married
control was selected from women inpatients in the
same hospital who had certain acute medical or
surgical conditions or had been admitted for
routine elective operations that were considered
unlikely to be associated with the use or lack of use
of any contraceptive. The control women matched
the women with breast cancer within 5-year age
groups (within 5 years of age prior to 1972) and
within parity groups (nil, 1 or 2, or >3 term births)
and were interviewed in the same way.
Some of the hospitals were added during the
course of the study and there were minor differences
between the procedures at different periods which
were described in our earlier reports. The only
important difference was that the upper limit of the
age range of the breast cancer patients interviewed
was 39y until the end of 1971, and 45y from 1972
to mid-1974.
Up to the end of August 1977, the case notes of
each patient with cancer treated at any of the
London hospitals were reviewed (usually by MV),
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the treatment was recorded, and clinical
information was abstracted to enable the tumour to
be staged according to the TNM system
(International Union against Cancer, 1968). So far
as possible, this procedure was carried out in the
absence of information about the contraceptive
practices of the patient concerned. From the
beginning of September 1977, the review of the case
notes and extraction of clinical information was
dropped. All patients with breast cancer treated at
the London hospitals have, however, been followed
up annually and those dying have been identified.
In the present report the overall results are first
presented as simple contingency tables that take no
account of the matched design of the study. In
subsequent analyses relative risks are estimated,
allowance is made for confounding variables, and
interactions are sought, using the "adapted" linear
logistic procedure described by Breslow et al. (1978).
This method preserves the matching and entails
fitting mathematical models for specified sets of
variables thought to influence the risk of the
disease.
Of the 1176 women with breast cancer, 210
(17.9%) were aged 16-35y, 257 (21.9%) 36-40y, 388
(33.0%) 41-45y and 321 (27.2%) 46-50y. One
hundred and twenty-seven (10.8%) of the women
were nulliparous, 648 (55.1%) had 1 or 2 term births
and 401 (34.1%) had .3 term births.
Results
Use oforal contraceptives
As in our earlier analyses, the reference point used
to assess the contraceptive histories of the women
with breast cancer was taken as the time when the
patient first became aware of a lump (or other
abnormality) in her breast, with corresponding
times for the matched controls.
Table I shows the numbers of patients in each
group who had been using the pill during the
month before the lump was first detected (or during
the corresponding month for the controls) together
with the numbers who had used oral contraceptives
only before that time. Table II shows the interval
between the time the pill was first used and the time
the lump was detected, and Table III the total
duration of oral contraceptive use. In general, there
is close agreement between the data for the breast
cancer cases and the controls although Tables I and
II indicate that a slightly higher proportion of
controls than of cases reported use of oral
contraceptives in the distant past.
Table IV provides some simple information about
the types of oral contraceptive used by cases and
controls. No important differences are apparent. In
addition, we made comparisons between the groups
on a brand name basis-once again we could detect
no evidence of other than random variation.
Comparability ofthe groups
The controls were selected for their comparability
with the patients with breast cancer with respect to
age, parity, marital state and date and hospital of
admission. They were also found to be comparable
with regard to religion, country of origin, and
whether pregnant or in the puerperium. As
described in our last full report (Vessey et al., 1979),
the breast cancer patients were of higher social
class, had an earlier age at menarche and later age
at first term birth, were less often postmenopausal,
and more frequently had a history of breast biopsy
and a family history of breast cancer than the
controls. All these differences are, of course,
consistent with the known epidemiology of the
disease (Kalache & Vessey, 1982).
In a previous analysis of 621 pairs of patients
(Vessey et al., 1979) we noted that breast cancer
patients were less likely to be heavy cigarette
Table I Use of oral contraceptives by women with breast cancer and matched
controls classified by time when last used
Time when last used before Number (%) with Number (%) of
lump detected (months) breast cancer controls
During month before 142 (12.1) 129 (11.0)
More than one month before:
412 58 69
13-48 122 l 395 (33.6) 119 425 (36.1)
49-96 125 o101
97 90- 136-
Never used 639 (54.3) 622 (52.9)
Total 1176 (100.0) 1176 (100.0)ORAL CONTRACEPTIVES AND BREAST CANCER 457
Table II Use of oral contraceptives by women with
breast cancer and matched controls classified by interval
since first used
Timefromfirst use
to detection of Number (%) with Number (0)
lump (months) breast cancer ofcontrols
< 12 21 (1.8) 26 (2.2)
13-48 79 (6.7) 86 (7.3)
49-96 172 (14.7) 142 (12.1)
97-144 153 (13.0) 146 (12.4)
> 145 112 (9.5) 154 (13.1)
Never used 639 (54.3) 622 (52.9)
Total 1176 (100.0) 1176 (100.0)
Table III Total duration of oral contraceptive use by
women with breast cancer and matched controls
Total duration Number (%) with Number (%)
use (months) breast cancer ofcontrols
< 12 203 (17.3) 234 (19.9)
13-48 145 (12.3) 146 (12.4)
49-96 123 (10.5) 108 (9.2)
97-144 49 (4.2) 42 (3.6)
> 145 17 (1.4) 24 (2.0)
Never used 639 (54.3) 622 (52.9)
Total 1176 (100.0) 1176 (100.0)
Table IV Numbers of women with breast cancer and




Type ofpreparation breast cancer ofcontrols*
High oestrogen () 100jug) 142 (12.1) 138 (11.7)
Medium oestrogen (75-80,pg) 45 (3.8) 31 (2.6)
Low oestrogen ( 50Opg) 304 (25.9) 272 (23.1)
Progestogen alone 33 (2.8) 29 (2.5)
Unknown 155 (13.2) 180 (15.3)
None used 639 (54.3) 622 (52.9)
*Some women in both groups reported using more then
one type so the numbers sum to more than 1176
smokers (,e 15 cigarettes per day) than controls.
This difference was maintained in the later part of
the study and was clearly apparent in the complete
data (Table V) from which it was estimated that the
"relative risk" of breast cancer in heavy smokers in
comparison with non-smokers is 0.54:1 (test for
trend on data in Table V, P<0.001). We undertook
a series of analyses to see if this negative association
Table V Cigarette smoking habits of women with breast
cancer and matched controls
Cigarettes smoked Number (%) with Number (%)
per day breast cancer ofcontrols
None ever 596 (50.7)* 486 (41.3)*
Ex-smokers 168 (14.3) 162 (13.8)
1-14 180 (15.3) 202 (17.2)
> 15 232 (19.7)* 326 (27.7)*
Total 1176 (100.0) 1176 (100.0)
*In the first 621 pairs of patients, the percentages of
current non-smokers (i.e. those who never smoked plus ex-
smokers) were 60.9 and 54.4 and of heavy cigarette
smokers were 20.8 and 28.0.
was merely a reflection of other differences between
the women with breast cancer and the controls,
especially in terms of social class and age at first
term birth. Such adjustment, however, while
reducing the smoking association, by no means
eliminated it (adjusted relative risk, heavy
smokers:non-smokers, 0.67:1, test for trend,
P<0.001).
Finally, we examined the use of other reversible
methods of contraception by the women in the two
groups. Unfortunately, the data available were very
rudimentary as we had merely asked each woman if
she (or her husband) had at any time used the
sheath, the diaphragm, an intrauterine device,
withdrawal, the safe period or other birth control
methods. The results are shown in Table VI. As in
our last analysis, there is no suggestion that the
women with breast cancer had any less need of
contraception than the controls. Indeed, the
converse is true; 16.6% of the controls, but only
10.2% of the cancer patients said they had never
used any method of birth control (16.9% and 10.0%
respectively in our last analysis of 621 pairs of
patients). Little of this difference was explicable in
terms of other variables such as social class. A
Table VI Numbers of women with breast cancer and
matched controls reporting having ever used certain
reversible methods of contraception
Number (%) with Number (%)
Method breast cancer ofcontrols
Sheath 645 (54.8) 546 (46.4)
Diaphragm 308 (26.2) 236 (20.1)
Withdrawal 168 (14.3) 164 (13.9)
Intrauterine device 136 (11.6) 142 (12.1)
Safe period 77 (6.5) 53 (4.5)
Other 74 (6.3) 66 (5.6)
None ever used 120 (10.2) 195 (16.6)458 M. VESSEY et al.
detailed examination of the characteristics of the
120 breast cancer patients and 195 controls who did
not admit to the use of birth control was not
particularly helpful, although it should be noted
that only 30 (25%) of the former and 38 (19%) of
the latter had never had any children while the
corresponding figures for those having > 3 children
were 35 (29.2%) and 56 (28.7%) respectively.
Multivariate analysis
In our first set of analyses using the method of
Breslow et al. (1978), four main measures of oral
contraceptive use were considered: use at any time;
interval since last use; interval since first use; and
total duration of use. The effects of social class (4
groups), age at menarche (3 groups), age at first
term birth (4 groups), menopausal state (3 groups),
history of breast biopsy (2 groups), family history of
breast cancer (2 groups) and cigarette smoking (3
groups) were incorporated into the model as
possible confounding variables, although, in the
event, they had little effect on the estimation of
relative risks (Vessey et al., 1979). Separate analyses
were made within 4 age groups (16-35, 36-40, 41-
45, 46-50) and 3 parity groups (0, 1-2, >3 children)
as well as for all the data combined. Table VII
summarises the results obtained overall and
according to age. In the three younger age groups,
there are two statistically significant values of X2 for
heterogeneity but no patterns of risk emerge and it
seems reasonable to ascribe these apparent
Table VII Risk of breast cancer in relation to different measures of exposure to oral contraceptives by age. In
each analysis, risk among women never using oral contraceptives is taken as unity (95% confidence limits are
given in parentheses)
Age group (years)
16-35 36-40 41-45 46-50 All ages
No. ofpairs 210 257 388 321 1176
Use at any time:
No 1.00 1.00 1.00 1.00 1.00
Yes 0.94 0.86 0.72 1.50 0.98
(0.57-1.53) (0.56-1.31) (0.51-1.02) (1.04-2.16) (0.81-1.18)
X2 heterogeneity 0.07 0.51 3.41 4.77* 0.05
Interval since last
used (months)
Never 1.00 1.00 1.00 1.00 1.00
-12 0.93 0.85 0.78 1.20 0.99 (0.76-1.30)
13-48 0.92 0.74 0.82 1.27 0.95 (0.70-1.31)
49-96 1.23 1.42 0.99 1.86 1.34 (0.98-1.83)
97+ 0.54 0.40 0.38 1.74 0.67 (0.48-0.94)
x4 heterogeneity 2.20 7.80 11.08* 6.09 10.50*
Interval since first
used (months)
Never 1.00 1.00 1.00 1.00 1.00
-48 0.58 0.98 0.62 1.31 0.83 (0.59-1.17)
49-96 1.24 1.14 0.84 1.82 1.20 (0.91-1.59)
97-144 1.05 0.79 1.15 1.80 1.17 (0.87-1.55)
145+ 1.32 0.55 0.43 1.23 0.73 (0.54-0.99)
X2 heterogeneity 5.59 3.94 12.20* 6.24 10.29*
X2 linear trend 0.55 2.03 4.85* 3.25 0.44
Total duration of
use (months)
Never 1.00 1.00 1.00 1.00 1.00
-12 0.79 0.70 0.60 1.72 0.88 (0.69-1.13)
13-48 0.76 1.29 0.76 1.71 1.01 (0.76-1.33)
49-96 1.62 0.87 0.71 1.28 1.16 (0.84-1.59)
97+ 1.01 0.71 1.01 1.07 0.99 (0.67-1.45)
X2 heterogeneity 6.73 3.67 5.52 6.11 2.43
xi linear trend 1.08 0.18 0.48 1.71 0.22
*P<0.05.
Risks adjusted for effects of social class, age at menarche, age at first term birth, menopausal state, smoking
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associations to chance. The increased relative risk
associated with oral contraceptive use in those aged
46-S50y (1.50:1) was also statistically significant,
although it should be noted that the biggest
deficiency of use in breast cancer patients occurred
in those just 5 years younger. In our last report
(Vessey et al., 1979), the relative risk for the 46-50y
age group (based on 115 case-control pairs) was
2.40:1 while the relative risk based on the 206 case-
control pairs interviewed since then is 1.39:1-i.e.
much smaller, but still elevated. There is, however,
little evidence of any pattern in the relative risks in
the 46-50y age group in the remainder of Table
VII in particular, there is no evidence that either
very long durations of oral contraceptive use or use
in the very distant past is associated with an
increased risk. Despite this, we decided to take a
close look at oral contraceptive use in women aged
46-50 y (and, for comparative purposes, in those
aged 41-45y) in relation to menopausal state. Some
simple results are given in Table VIII from which it
can be seen that the slight excess of oral
contraceptive use among women with breast cancer
in the older age group is apparent in all three
menopause subcategories. More sophisticated
analysis of the data using the method of Breslow et
al. (1978) confirmed that menopausal state was not
an important "modifier" of the effect of oral
contraceptive use in those aged 46-50y.
In a second series of analyses, we examined the
effects of different types of oral contraceptives.
Again, separate analyses were made within age and
parity subgroups as well as overall. We were unable
to discern any pattern in the large array of relative
risks calculated. In particular, the two associations
which were statistically significant in our last
analysis (an increased risk associated with
preparations containing 75-80 ug oestrogen in
women aged 36-40y and a decreased risk
associated with preparations of unknown type in
women aged 41-45y) were not apparent in the data
collected during the last 3 years of the study.
Finally, we searched for evidence of any
interactions between oral contraceptive use and late
age at first term birth, a history of breast biopsy,
and a family history of breast cancer. Table IX
gives the basic data (subdivided by total duration of
use) which provide little indication of any effect; this
was confirmed by multivariate analysis. The
numbers of subjects included in most of the
analyses were, however, small despite the large size
of the study overall.
Use of oral contraceptives before the first term
birth has been the subject of a separate publication
(Vessey et al., 1982). No evidence of any deleterious
effect was found.
Use ofhormone replacement therapy
During the last 3 years of the study, questions were
asked about the use of hormone replacement
therapy as well as about oral contraceptive use. As
expected, use of such therapy was infrequent.
Among 555 women with breast cancer, 34 (6.1%)
reported use of replacement therapy of whom 8
(1.4%) reported more than one year's use. Among
the controls, the corresponding figures were 37
(6.7%) and 11 (2.0%).
Diagnostic bias
In our last general report (Vessey et al., 1979) we
presented data for users and non-users of oral
contraceptives about delay in seeking treatment for
breast cancer, about the identity of the individual
who first discovered the tumour and about the
prevalence of regular breast self examination. We
Table VIII Oral contraceptive use by age and menopausal state
% with % with
% ever recent % using % ever recent % using
Menopausal No. using pill pill No. using pill pill
Age state cases pill use* >48 mo. controls pill use* >48 mo.
41-45 Pre 355 36.3 11.8 14.9 293 42.3 13.3 15.7
Natural 7 0 0 0 18 16.7 0 5.6
Artificial 26 50.0 3.8 15.4 77 45.5 1.3 7.8
Total 388 36.6 11.1 14.7 388 41.8 10.3 13.7
46-50 Pre 220 36.8 10.9 15.0 167 32.3 9.6 12.0
Natural 49 28.6 0 8.2 69 21.7 7.2 5.8
Artificial 52 40.4 3.8 3.8 85 30.6 2.4 7.1
Total 321 36.1 8.1 12.1 321 29.6 7.2 9.3
*"Recent" pill use-use within the 12 months prior to diagnosis.460 M. VESSEY et al.
Table IX Total duration of oral contraceptive use in
various subgroups of patients with breast cancer and
controls
Duration oforal
contraceptive use Number (%) Number (%)
(mo.) with cancer ofcontrols
Parous patients aged 26 or more at 1st term birth
Never 284 (64.0) 181 (59.0)
<48 107 (24.1) 93 (30.3)
49+ 53 (11.9) 33 (10.7)
Total 444 (100.0) 307 (100.0)
Patients with history of breast biopsy
Never 67 (65.0) 41 (56.9)
<48 29 (28.2) 25 (34.7)
49+ 7 (6.8) 6 (8.3)





Patients with family history of breast cancer
62 (59.0) 32 (52.5)
26 (24.8) 21 (34.4)
17 (16.2) 8 (13.1)
105 (100.0) 61 (100.0)
came to the conclusion that there was little evidence
that anxiety about the possible relationship between
pill use and breast cancer was leading to diagnostic
bias. The additional data available in the present
analysis (not shown) have not altered this
conclusion.
Clinical stage ofbreast tumours
Table X gives the clinical stage classification of 572
of the 582 patients treated for breast cancer at the
London hospitals up to the end of August 1977; no
stage could be assigned to the remaining 10 because
of inadequate clinical information in the records.
As before, women who had never used oral
contraceptives had appreciably more advanced
tumours than those who had been using oral
contraceptives during the year before detection of
the lump ("recent" users), while past users were in
an intermediate position.
Mortality ofpatients with breast tumours
Of the 572 women with breast cancer included in
Table X, 562 were followed until the end of
December 1979. There were 182 deaths. All 10
patients who were not followed had emigrated; no
attempt was made to trace them after their
departure.
Table XI gives an analysis of mortality, using the
log rank method (Peto et al., 1977), in relation to
oral contraceptive use at the time the tumour was
first detected. As in our last analysis, recent users
of the pill had a lower mortality than past users,
who in turn had a lower mortality than those who
had never used the pill. These differences were,
however, small and not statistically significant; they
almost entirely disappeared after allowance had
been made for the effect of clinical stage on
survival.
Discussion
Since the appearance of our last detailed report
(Vessey et al., 1979), the results of a considerable
number of additional epidemiological studies of the
possible association between oral contraceptive use
and breast cancer have been published
(Paffenbarger et al., 1979; Ravnihar et al., 1979;
Jick et al., 1980; Matthews et al., 1981; Pike et al.,
1981; Royal College of General Practitioners, 1981;
Vessey et al., 1981; Trapido, 1981; Harris et al.,
Table X Stage classification of 572 patients with breast cancer (TNM
system) treated at the London hospitals before the end of August, 1977.
Figures are numbers of patients (percentages in parentheses)
Use oforal contraceptives*
Used only Used
Clinical stage Never used in past recently
I (T,-2' No. Mo) 196 (55.4) 83 (64.3) 66 (74.2)
II (TI-2, N1, MO) 74 (20.8) 23 (17.8) 11 (12.4)
III-IV (other TNM
categories) 84 (23.8) 23 (18.0) 12 (13.4)
Total 354 (100.0) 129 (100.0) 89 (100.0)
*"Used recently" indicates use during year before detection of lump.
"Used only in past" indicates use only before that time.
X4 11.75; P=0.02.ORAL CONTRACEPTIVES AND BREAST CANCER
Table XI Mortality among 572 patients with breast cancer treated at the London
hospitals before the end of August, 1977. Closure date for analysis 31st December,
1979. Analysis by log rank method (Peto et al., 1977)
Use oforal contraceptives:
Never Used only Used X(2) linear
Number ofdeaths: used in past recently trend
Observed 120 37 25
Expected:
Unadjusted for stage 112.5 39.0 30.5 1.60 (NS)
Adjusted for stage 118.1 36.8 27.1 0.17 (NS)
1982). The results of these studies have mostly been
reassuring, but Jick et al. (1981) suggested that
recent (within a year) oral contraceptive use might
be hazardous in premenopausal women aged 46-
55y, while Pike et al. (1981) and Harris et al.
(1982) found an increased risk to be associated with
oral contraceptive use before first full term
pregnancy. In the study by Pike et al. (1981), which
dealt only with women with breast cancer aged up
to 32y, this harmful effect was apparent only after
4 years pill use. Our data (both those appearing in
the present report and those appearing in Vessey et
al. (1982)) offer no support to these positive results
and, on balance, give no cause for concern. A few
statistically significant differences in oral
contraceptive use were found between the breast
cancer and control groups, but the data were
subdivided in so many ways that some "significant"
differences would have been expected to occur
through the play of chance alone. Certainly no
patterns of risk have emerged which seem to us to
point towards a causal association between pill use
and the occurrence of breast cancer. It must be
stressed, however, that the data are still sparse in
some important sub categories-for example, only
small numbers of both cases and controls in our
study had prolonged oral contraceptive use before
their first term pregnancy. For this reason, it is
important that data on the possible relationship
between oral contraceptive use and breast cancer
should continue to be collected.
A large, carefully designed, and well-conducted
case-control study of oral contraceptive use and
breast cancer, funded by the National Institutes of
Health, is at present being conducted by the Family
Planning Evaluation Division of the Centers for
Disease Control in Atlanta. In contrast with most
other case-control studies of this question, this
investigation is using community controls rather
than hospital controls. Although no formal paper
describing the preliminary results of the study has
yet been published, a number of reports concerning
the first 689 cases and 1072 controls have appeared
indicating that no evidence has been found that
breast cancer risk is influenced by pill use
(Anonymous, 1982).
In our last full analysis (Vessey et al., 1979), we
noted that a smaller proportion of women with
breast cancer than of matched controls reported
never having used any method of birth control at
all. The addition of data for a further 555 pairs of
patients has left this association unchanged. As a
possible explanation, we suggested in 1979 that
infertile women, who have less need for
contraception, might be less likely to develop breast
cancer than fertile women. Our examination of the
characteristics of the 120 breast cancer patients and
190 controls who did not admit to the use of birth
control, however, makes this explanation unlikely-
only 25% of the former and 19% of the latter had
never had any children. We are therefore at
something of a loss to explain the difference,
although it might, perhaps, mean that women with
breast cancer, because of the nature of their illness,
are more likely to admit to the use of contraception
than controls. Certainly it could be argued that the
risks of breast cancer associated with oral
contraception should be estimated only from data
relating to patients and controls admitting to the
use of some birth control method. We have chosen
not to adopt this approach in the present paper but
it may be noted that, on this basis, the adjusted
relative risk of breast cancer among those with any
use of oral contraceptives is only 0.80 (as opposed
to 0.98 see Table VII).
The negative association between cigarette
smoking and breast cancer was noted in our last
full report and has now been consolidated by the
collection of additional data. We have been unable
to explain the association in terms of any known
confounding variable. It is, of course, established
that, on average, cigarette smokers have an earlier
age of natural menopause than non-smokers (Jick et
al., 1977) and, as a consequence, post-menopausal
smokers would be expected to be at slightly lower
risk of breast cancer than non-smokers. The
association that we have observed cannot, however,
be explained in terms of this mechanism. It is also
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possible that smoking might offer some additional
protection against breast cancer (MacMahon et al.,
1982; Baron J., personal communication), but we
suspect that the unrepresentative nature of smoking
habits amongst our hospital controls-in some of
whom cigarette smoking is likely to have
contributed to their ill-health-is a likely
explanation for our results.
Finally, the small amount of additional
information in the present report on clinical stage
of breast tumours at diagnosis supports our earlier
observation of a negative association between stage
and oral contraceptive use. Once again, we found
no evidence that this association can be attributed
to "surveillance bias" among oral contraceptive
users and the possibility of a beneficial effect of
contraceptive steroids on tumour growth and
spread must be considered.
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